Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Finds Conflict-Affected Countries Receive Less Money For Reproductive Health
A recent study found developing countries affected by war receive less money for reproductive health than other developing nations, despite having acute needs, Reuters reports. "In war-affected countries, 1,041 pregnant women die for every 100,000 live births due to complications such as bleeding, infections and obstructed labour" compared to 720 maternal deaths for every 100,000 live births in "underdeveloped countries that were unaffected by war," Reuters writes. Nine women die for every 100,000 live births "in advanced countries with modern healthcare facilities," according to Reuters.

UCSF Nurses To Picket Hospital Over "Dangerous" New Staffing Policies
Protesting what they call a "dangerous and frightening" reduction in medical res, Registered Nurses from UCSF will picket their hospital this Wednesday, calling on administrators to immediately withdraw their proposal to increase patient loads for nurses by 25 to 100 percent.
News of the day
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict From Abbott Laboratories
Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit.
Health Insurance

Forsyth Medical Center Participating In Avastin Trial For New Glioblastoma Patients

The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the brain or spinal cord. Forsyth Regional Cancer Center (FRCC) is participating in the third phase of the trial, testing the effectiveness of Avastin in conjunction with standard chemotherapy and radiation treatments for patients newly diagnosed with glioblastoma. This phase of the trial will enroll 700 participants nationwide, and FRCC is one of the first sites in the country to participate. The trial is part of the hospital"s neurosciences program. "Avastin has been shown to be effective in treating various types of cancer, with a low risk of serious side effects, so our hope is that it will improve outcomes for patients with brain tumors when it is added to standard-of-care treatments," says Volker Stieber, M.D., a radiation oncologist at the FRCC. "Phase III is the highest level of research for a drug, so we are excited to be part of a study that could advance treatment for patients with this type of cancer." In May, the U.S. Food and Drug Administration approved the use of Avastin to treat glioblastomas that have not responded to other therapies based on results from two Phase II studies that showed Avastin reduced tumor size in some glioblastoma patients. The new study evaluates this drug in newly diagnosed, never-treated glioblastoma patients. Glioblastoma is the most common and most aggressive type of primary brain tumor in humans, accounting for about half of all primary brain tumor cases. Despite its prevalence, however, glioblastomas occur in only two to three cases per 100,000 people in North America and Europe. In Forsyth County, three out of four patients diagnosed with glioblastoma are diagnosed at Forsyth Medical Center. The FRCC is currently screening patients for enrollment in the clinical trial. Eligible patients may qualify if they are newly diagnosed adults able to undergo partial removal of their tumors. Once enrolled, participants will remain in the study for up to one year. Freda Springs Forsyth Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009